These modifications in the activation status of cDC1- and cDC2-like cells after tumor cell contact subsequently resulted in significantly enhanced CD8<sup>+</sup> and CD4<sup>+</sup> T cell proliferation.<h4>Conclusion</h4>Current glioblastoma cell treatment impacts on the subsequent activation of cDCs and T cells and should serve as basis for improving immunotherapeutic strategies of brain tumors. This evidence concerns the gene CD8A and glioblastoma.